SCHEMBL424342

SCHEMBL424342

CN(C(=O)n1nnc2ccccc21)C1CCCCC1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 2/20 0.53
KMT2A Q03164 3/20 0.50
ALDH1A1 P00352 2/20 0.50
KDM4E B2RXH2 1/20 0.50
MAPT P10636 1/20 0.50
HTT P42858 1/20 0.50
NPSR1 Q6W5P4 1/20 0.50
MGLL Q99685 2/20 0.47
TRPA1 O75762 1/20 0.47
GAA P10253 7/20 0.47
MGAM O43451 6/20 0.47
AMY1A P0DUB6 6/20 0.47
SI P14410 6/20 0.47
MGAM2 Q2M2H8 6/20 0.47
F2 P00734 2/20 0.47
HPGD P15428 1/20 0.47
SLC9A1 P19634 1/20 0.47
PTAFR P25105 1/20 0.46
USP2 O75604 1/20 0.44
DGAT1 O75907 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL424622 0.99 KMT2A (0.51) TRPV1KMT2AALDH1A1KDM4EMAPT
SCHEMBL427899 0.88 KMT2A (0.49) TRPV1KMT2AALDH1A1KDM4EMAPT
SCHEMBL427408 0.87 KMT2A (0.48) KMT2AALDH1A1KDM4EMAPTHTT
SCHEMBL427321 0.84 L3MBTL1 (0.47) KMT2AALDH1A1KDM4EMAPTHTT
SCHEMBL425717 0.84 TRPV1 (0.45) TRPV1KMT2AALDH1A1KDM4EMAPT
SCHEMBL427875 0.83 HCAR3 (0.46) TRPV1KMT2AALDH1A1KDM4EMAPT
SCHEMBL425471 0.83 TRPV1 (0.44) TRPV1ALDH1A1NPSR1MGLLTRPA1
SCHEMBL427404 0.82 HCAR3 (0.44) TRPV1KMT2AALDH1A1KDM4EMAPT
SCHEMBL7899251 0.82 TRPV1 (0.43) TRPV1KMT2AALDH1A1MAPTMGLL
SCHEMBL424469 0.81 KMT2A (0.43) TRPV1KMT2AALDH1A1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
WO-2010074588-A2 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2010-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS FAAH, FAAH2, ASAH1 TRPV1 165/4885KMT2A 2067/4885ALDH1A1 294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.